Drug Index


Mechanism :

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) for oral administration. The antidepressant, antiobsessive-compulsive, and antibulimic actions of fluoxetine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.

Indication :

  • Obsessive compulsive disorder
  • Panic disorder
  • Anxiety disorder
  • Social phobia
  • Idiopathic musculoskeletal pain

Contraindications :

Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) and pimozide is contraindicated. Also contraindicated in patients with a hypersensitivity to fluoxetine, hepatic or renal insufficiency.

Dosing :

Paroxetine is not FDA-approved for use in children and adolescents less than 18 years of age.
Obsessive compulsive disorder (OCD):
Oral: 12-18 years: 20 mg once daily in the morning. Increase weekly by 10 mg/day to max dose of 60 mg.
Panic disorder:
Oral: 12-18 years: 10 mg once daily in the morning. Increase weekly by 10 mg/day to max dose of 40 mg.
Idiopathic musculoskeletal pain:
Oral: 8-12 years: 10 mg and 12-18 years: 20 mg once a day.

Adverse Effect :

Commonly seen side effects are nausea and gastrointestinal symptoms generally. Headache, light headedness, restlessness, anxiety, weight loss, seizures, rash, urticaria, fever, neuroleptic malignant syndrome, social disinhibition, euphoria, precipitation of mania, diminished libido and anorgasmia may be seen.

Interaction :

Lithium: There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with paroxetine.
Tryptophan: Adverse reactions, including agitation, restlessness, and gastrointestinal distress.
Benzodiazepines: Half-life of concurrently administered diazepam may be prolonged in some patients. Coadministration of alprazolam and paroxetine has resulted in increased alprazolam plasma concentrations.
Haloperidol and Clozapine: Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant paroxetine.
Carbamazepine: Elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant paroxetine treatment.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
30-50Dose as in normal renal function
10-3020 mg daily and titrate slowly
<1020 mg daily and titrate slowly

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as for GFR=10–30 mL/min

Hepatic Dose :

Mild to moderate hepatic impairment: Dose adjustment guidelines are not available, dose adjustment may not be required, plasma levels do increase in hepatic impairment so caution should be taken, and levels should be monitored.
Severe hepatic impairment: decrease dose by 50% to 5 mg/day. Increase every 1-2 weeks by 5mg to a maximum dose of 25mg/day.
02/16/2024 17:40:19 Paroxetine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0